Photo from archive.org
Approximately 4% of patients with melanoma will experience in-transit metastases (ITMs). These patients are at high risk for further (distant) metastasis and have a grim prognosis. Multiple locoregional and systemic… Click to show full abstract
Approximately 4% of patients with melanoma will experience in-transit metastases (ITMs). These patients are at high risk for further (distant) metastasis and have a grim prognosis. Multiple locoregional and systemic therapy options are available these patients. Careful assessment for further locoregional disease and distant metastases is important to guide selection of the most appropriate treatment and to determine prognosis more accurately. However, despite a range of available diagnostic methods, no strategy has been generally accepted for these patients.
Journal Title: Annals of Surgical Oncology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!